AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) is now covered by analysts at Credit Suisse Group AG. They set an "outperform" rating on the stock.
AcelRx Pharmaceuticals, Inc. (ACRX)
Last acelrx pharmaceuticals, inc. earnings: 3/16 07:35 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.acelrx.com/investor-relations
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
ACRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACRX alerts
High impacting AcelRx Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ACRX
News
- AcelRx Pharmaceuticals Announces Publication of an Article Highlighting the Utility of the Sufentanil Sublingual Tablet in Pain Medicine ProceduresPR Newswire
- AcelRx Pharmaceuticals: The Fog Is Getting Thicker [Seeking Alpha]Seeking Alpha
- AcelRx Pharmaceuticals Announces Publication of an Editorial by an Internationally Recognized Leader in Opioid-Sparing Surgery Highlighting the Potential Advantages of the Sufentanil Sublingual Tablet in Joint Replacement SurgeryPR Newswire
- AcelRx Pharmaceuticals Announces the Closing of its Acquisition of Lowell TherapeuticsPR Newswire
- AcelRx Pharmaceuticals Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement SurgeryPR Newswire
ACRX
Earnings
- 11/15/21 - In-Line
ACRX
Analyst Actions
- 11/18/21 - Zacks Investment Research
ACRX
Sec Filings
- 1/27/22 - Form SC
- 1/24/22 - Form D
- 1/12/22 - Form 8-K
- ACRX's page on the SEC website